#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=In many clinical specialties , there exists a high variety of image modalities that clinicians typically use to analyze the patient ’s condition and aid in the diagnostic process .
2-1	16-18	In	_	_	_	_
2-2	19-23	many	abstract[2]	new[2]	_	_
2-3	24-32	clinical	abstract[2]	new[2]	_	_
2-4	33-44	specialties	abstract[2]	new[2]	_	_
2-5	45-46	,	_	_	_	_
2-6	47-52	there	_	_	_	_
2-7	53-59	exists	_	_	_	_
2-8	60-61	a	abstract[3]	new[3]	_	_
2-9	62-66	high	abstract[3]	new[3]	_	_
2-10	67-74	variety	abstract[3]	new[3]	_	_
2-11	75-77	of	abstract[3]	new[3]	_	_
2-12	78-83	image	abstract[3]|abstract|abstract[5]	new[3]|new|new[5]	coref|coref	5-2|6-4[47_5]
2-13	84-94	modalities	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-14	95-99	that	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-15	100-110	clinicians	abstract[3]|abstract[5]|person	new[3]|new[5]|new	_	_
2-16	111-120	typically	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-17	121-124	use	abstract[3]|abstract[5]	new[3]|new[5]	_	_
2-18	125-127	to	_	_	_	_
2-19	128-135	analyze	_	_	_	_
2-20	136-139	the	abstract[8]	new[8]	_	_
2-21	140-147	patient	person[7]|abstract[8]	new[7]|new[8]	coref	8-28[70_7]
2-22	148-150	’s	person[7]|abstract[8]	new[7]|new[8]	_	_
2-23	151-160	condition	abstract[8]	new[8]	_	_
2-24	161-164	and	_	_	_	_
2-25	165-168	aid	_	_	_	_
2-26	169-171	in	_	_	_	_
2-27	172-175	the	event[9]	new[9]	coref	20-10[155_9]
2-28	176-186	diagnostic	event[9]	new[9]	_	_
2-29	187-194	process	event[9]	new[9]	_	_
2-30	195-196	.	_	_	_	_

#Text=Given the importance of technology at present , namely , its inclusion in different areas to improve an expert ’s work , many computational systems have been implemented to facilitate this clinical processes .
3-1	197-202	Given	_	_	_	_
3-2	203-206	the	abstract[10]	new[10]	_	_
3-3	207-217	importance	abstract[10]	new[10]	_	_
3-4	218-220	of	abstract[10]	new[10]	_	_
3-5	221-231	technology	abstract[10]|abstract[11]	new[10]|new[11]	ana	3-11[0_11]
3-6	232-234	at	abstract[10]|abstract[11]	new[10]|new[11]	_	_
3-7	235-242	present	abstract[10]|abstract[11]|time	new[10]|new[11]|new	_	_
3-8	243-244	,	_	_	_	_
3-9	245-251	namely	person[14]	new[14]	_	_
3-10	252-253	,	person[14]	new[14]	_	_
3-11	254-257	its	abstract|person[14]	giv|new[14]	_	_
3-12	258-267	inclusion	person[14]	new[14]	_	_
3-13	268-270	in	person[14]	new[14]	_	_
3-14	271-280	different	person[14]|abstract[15]	new[14]|new[15]	coref	5-25[34_15]
3-15	281-286	areas	person[14]|abstract[15]	new[14]|new[15]	_	_
3-16	287-289	to	person[14]	new[14]	_	_
3-17	290-297	improve	person[14]	new[14]	_	_
3-18	298-300	an	person[14]|abstract[17]	new[14]|new[17]	_	_
3-19	301-307	expert	person[14]|person[16]|abstract[17]	new[14]|new[16]|new[17]	coref	4-19[25_16]
3-20	308-310	’s	person[14]|person[16]|abstract[17]	new[14]|new[16]|new[17]	_	_
3-21	311-315	work	person[14]|abstract[17]	new[14]|new[17]	_	_
3-22	316-317	,	_	_	_	_
3-23	318-322	many	abstract[18]	new[18]	coref	5-53[44_18]
3-24	323-336	computational	abstract[18]	new[18]	_	_
3-25	337-344	systems	abstract[18]	new[18]	_	_
3-26	345-349	have	_	_	_	_
3-27	350-354	been	_	_	_	_
3-28	355-366	implemented	_	_	_	_
3-29	367-369	to	_	_	_	_
3-30	370-380	facilitate	_	_	_	_
3-31	381-385	this	abstract[19]	new[19]	coref	14-30[112_19]
3-32	386-394	clinical	abstract[19]	new[19]	_	_
3-33	395-404	processes	abstract[19]	new[19]	_	_
3-34	405-406	.	_	_	_	_

#Text=This automatization of different clinical manual tasks provide solutions and improvements that are characterized by desirable properties that the expert cannot offer such as determinism , repeatability or objectivity .
4-1	407-411	This	abstract[20]	new[20]	_	_
4-2	412-426	automatization	abstract[20]	new[20]	_	_
4-3	427-429	of	abstract[20]	new[20]	_	_
4-4	430-439	different	abstract[20]|abstract[21]	new[20]|new[21]	_	_
4-5	440-448	clinical	abstract[20]|abstract[21]	new[20]|new[21]	_	_
4-6	449-455	manual	abstract[20]|abstract[21]	new[20]|new[21]	_	_
4-7	456-461	tasks	abstract[20]|abstract[21]	new[20]|new[21]	_	_
4-8	462-469	provide	_	_	_	_
4-9	470-479	solutions	abstract	new	_	_
4-10	480-483	and	_	_	_	_
4-11	484-496	improvements	abstract[23]	new[23]	_	_
4-12	497-501	that	abstract[23]	new[23]	_	_
4-13	502-505	are	abstract[23]	new[23]	_	_
4-14	506-519	characterized	abstract[23]	new[23]	_	_
4-15	520-522	by	abstract[23]	new[23]	_	_
4-16	523-532	desirable	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-17	533-543	properties	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-18	544-548	that	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-19	549-552	the	abstract[23]|abstract[24]|person[25]	new[23]|new[24]|giv[25]	_	_
4-20	553-559	expert	abstract[23]|abstract[24]|person[25]	new[23]|new[24]|giv[25]	_	_
4-21	560-566	cannot	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-22	567-572	offer	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-23	573-577	such	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-24	578-580	as	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-25	581-592	determinism	abstract[23]|abstract[24]|abstract	new[23]|new[24]|new	_	_
4-26	593-594	,	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-27	595-608	repeatability	abstract[23]|abstract[24]|abstract	new[23]|new[24]|new	_	_
4-28	609-611	or	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-29	612-623	objectivity	abstract[23]|abstract[24]|abstract	new[23]|new[24]|new	_	_
4-30	624-625	.	_	_	_	_

#Text=Regarding image analysis , over the years , many computational proposals have been presented based on computer vision techniques that are exploited to analyze relevant areas of the images of interest , measure relevant parameters and monitor their evolution and potential variations , which is the typical procedure that is used in many Computer Aided Diagnostic ( CAD ) systems .
5-1	626-635	Regarding	_	_	_	_
5-2	636-641	image	abstract|abstract[30]	giv|new[30]	coref|coref	6-5|11-17[95_30]
5-3	642-650	analysis	abstract[30]	new[30]	_	_
5-4	651-652	,	_	_	_	_
5-5	653-657	over	_	_	_	_
5-6	658-661	the	_	_	_	_
5-7	662-667	years	_	_	_	_
5-8	668-669	,	_	_	_	_
5-9	670-674	many	abstract[31]	new[31]	_	_
5-10	675-688	computational	abstract[31]	new[31]	_	_
5-11	689-698	proposals	abstract[31]	new[31]	_	_
5-12	699-703	have	_	_	_	_
5-13	704-708	been	_	_	_	_
5-14	709-718	presented	_	_	_	_
5-15	719-724	based	_	_	_	_
5-16	725-727	on	_	_	_	_
5-17	728-736	computer	abstract[32]|abstract[33]	new[32]|new[33]	ana|coref	5-38[0_33]|16-19[0_32]
5-18	737-743	vision	abstract[32]|abstract[33]	new[32]|new[33]	_	_
5-19	744-754	techniques	abstract[33]	new[33]	_	_
5-20	755-759	that	abstract[33]	new[33]	_	_
5-21	760-763	are	abstract[33]	new[33]	_	_
5-22	764-773	exploited	abstract[33]	new[33]	_	_
5-23	774-776	to	abstract[33]	new[33]	_	_
5-24	777-784	analyze	abstract[33]	new[33]	_	_
5-25	785-793	relevant	abstract[33]|abstract[34]	new[33]|giv[34]	_	_
5-26	794-799	areas	abstract[33]|abstract[34]	new[33]|giv[34]	_	_
5-27	800-802	of	abstract[33]|abstract[34]	new[33]|giv[34]	_	_
5-28	803-806	the	abstract[33]|abstract[34]|abstract[35]	new[33]|giv[34]|new[35]	coref	24-10[186_35]
5-29	807-813	images	abstract[33]|abstract[34]|abstract[35]	new[33]|giv[34]|new[35]	_	_
5-30	814-816	of	abstract[33]|abstract[34]|abstract[35]	new[33]|giv[34]|new[35]	_	_
5-31	817-825	interest	abstract[33]|abstract[34]|abstract[35]	new[33]|giv[34]|new[35]	_	_
5-32	826-827	,	abstract[33]	new[33]	_	_
5-33	828-835	measure	abstract[33]	new[33]	_	_
5-34	836-844	relevant	abstract[33]|abstract[36]	new[33]|new[36]	_	_
5-35	845-855	parameters	abstract[33]|abstract[36]	new[33]|new[36]	_	_
5-36	856-859	and	abstract[33]	new[33]	_	_
5-37	860-867	monitor	abstract[33]	new[33]	_	_
5-38	868-873	their	abstract[33]|abstract|abstract[38]	new[33]|giv|new[38]	_	_
5-39	874-883	evolution	abstract[33]|abstract[38]	new[33]|new[38]	_	_
5-40	884-887	and	abstract[33]	new[33]	_	_
5-41	888-897	potential	abstract[33]|abstract[39]	new[33]|new[39]	_	_
5-42	898-908	variations	abstract[33]|abstract[39]	new[33]|new[39]	_	_
5-43	909-910	,	abstract[33]	new[33]	_	_
5-44	911-916	which	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-45	917-919	is	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-46	920-923	the	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-47	924-931	typical	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-48	932-941	procedure	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-49	942-946	that	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-50	947-949	is	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-51	950-954	used	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-52	955-957	in	abstract[33]|abstract[40]	new[33]|new[40]	_	_
5-53	958-962	many	abstract[33]|abstract[40]|abstract[44]	new[33]|new[40]|giv[44]	_	_
5-54	963-971	Computer	abstract[33]|abstract[40]|person[41]|abstract[42]|abstract[44]	new[33]|new[40]|new[41]|new[42]|giv[44]	appos	5-58[0_42]
5-55	972-977	Aided	abstract[33]|abstract[40]|person[41]|abstract[42]|abstract[44]	new[33]|new[40]|new[41]|new[42]|giv[44]	_	_
5-56	978-988	Diagnostic	abstract[33]|abstract[40]|abstract[42]|abstract[44]	new[33]|new[40]|new[42]|giv[44]	_	_
5-57	989-990	(	abstract[33]|abstract[40]|abstract[44]	new[33]|new[40]|giv[44]	_	_
5-58	991-994	CAD	abstract[33]|abstract[40]|abstract|abstract[44]	new[33]|new[40]|giv|giv[44]	_	_
5-59	995-996	)	abstract[33]|abstract[40]|abstract[44]	new[33]|new[40]|giv[44]	_	_
5-60	997-1004	systems	abstract[33]|abstract[40]|abstract[44]	new[33]|new[40]|giv[44]	_	_
5-61	1005-1006	.	_	_	_	_

#Text=In ophthalmology , different image modalities have increased in popularity over the last years .
6-1	1007-1009	In	_	_	_	_
6-2	1010-1023	ophthalmology	abstract	new	_	_
6-3	1024-1025	,	_	_	_	_
6-4	1026-1035	different	abstract[47]	giv[47]	_	_
6-5	1036-1041	image	abstract|abstract[47]	giv|giv[47]	coref	7-13
6-6	1042-1052	modalities	abstract[47]	giv[47]	_	_
6-7	1053-1057	have	_	_	_	_
6-8	1058-1067	increased	_	_	_	_
6-9	1068-1070	in	_	_	_	_
6-10	1071-1081	popularity	abstract	new	_	_
6-11	1082-1086	over	_	_	_	_
6-12	1087-1090	the	time[49]	new[49]	coref	22-11[165_49]
6-13	1091-1095	last	time[49]	new[49]	_	_
6-14	1096-1101	years	time[49]	new[49]	_	_
6-15	1102-1103	.	_	_	_	_

#Text=The color fundus retinography is the most traditional and widely extended ophthalmic image modality , that allows the direct visualization of the eye fundus and their possible pathological visible structures .
7-1	1104-1107	The	abstract[52]	new[52]	coref	7-6[54_52]
7-2	1108-1113	color	abstract|abstract[52]	new|new[52]	_	_
7-3	1114-1120	fundus	event|abstract[52]	new|new[52]	coref	7-22[57_0]
7-4	1121-1133	retinography	abstract[52]	new[52]	_	_
7-5	1134-1136	is	_	_	_	_
7-6	1137-1140	the	abstract[54]	giv[54]	coref	10-10[81_54]
7-7	1141-1145	most	abstract[54]	giv[54]	_	_
7-8	1146-1157	traditional	abstract[54]	giv[54]	_	_
7-9	1158-1161	and	abstract[54]	giv[54]	_	_
7-10	1162-1168	widely	abstract[54]	giv[54]	_	_
7-11	1169-1177	extended	abstract[54]	giv[54]	_	_
7-12	1178-1188	ophthalmic	abstract[54]	giv[54]	_	_
7-13	1189-1194	image	abstract|abstract[54]	giv|giv[54]	coref	10-12
7-14	1195-1203	modality	abstract[54]	giv[54]	_	_
7-15	1204-1205	,	abstract[54]	giv[54]	_	_
7-16	1206-1210	that	abstract[54]	giv[54]	_	_
7-17	1211-1217	allows	abstract[54]	giv[54]	_	_
7-18	1218-1221	the	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
7-19	1222-1228	direct	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
7-20	1229-1242	visualization	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
7-21	1243-1245	of	abstract[54]|abstract[55]	giv[54]|new[55]	_	_
7-22	1246-1249	the	abstract[54]|abstract[55]|event[57]|abstract[58]	giv[54]|new[55]|giv[57]|new[58]	ana	7-26[0_58]
7-23	1250-1253	eye	abstract[54]|abstract[55]|object|event[57]|abstract[58]	giv[54]|new[55]|new|giv[57]|new[58]	coref	13-12
7-24	1254-1260	fundus	abstract[54]|abstract[55]|event[57]|abstract[58]	giv[54]|new[55]|giv[57]|new[58]	_	_
7-25	1261-1264	and	abstract[54]|abstract[55]|abstract[58]	giv[54]|new[55]|new[58]	_	_
7-26	1265-1270	their	abstract[54]|abstract[55]|abstract[58]|abstract|abstract[60]	giv[54]|new[55]|new[58]|giv|new[60]	_	_
7-27	1271-1279	possible	abstract[54]|abstract[55]|abstract[58]|abstract[60]	giv[54]|new[55]|new[58]|new[60]	_	_
7-28	1280-1292	pathological	abstract[54]|abstract[55]|abstract[58]|abstract[60]	giv[54]|new[55]|new[58]|new[60]	_	_
7-29	1293-1300	visible	abstract[54]|abstract[55]|abstract[58]|abstract[60]	giv[54]|new[55]|new[58]|new[60]	_	_
7-30	1301-1311	structures	abstract[54]|abstract[55]|abstract[58]|abstract[60]	giv[54]|new[55]|new[58]|new[60]	_	_
7-31	1312-1313	.	_	_	_	_

#Text=Being an invasive capture technique , the Fluorescein Angiography ( FA ) provides an enhanced visualization of the retinal vascular structure by injecting a dye contrast into the patient .
8-1	1314-1319	Being	_	_	_	_
8-2	1320-1322	an	abstract[62]	new[62]	_	_
8-3	1323-1331	invasive	abstract[62]	new[62]	_	_
8-4	1332-1339	capture	event|abstract[62]	new|new[62]	_	_
8-5	1340-1349	technique	abstract[62]	new[62]	_	_
8-6	1350-1351	,	_	_	_	_
8-7	1352-1355	the	abstract[64]	new[64]	appos	8-11[0_64]
8-8	1356-1367	Fluorescein	person|abstract[64]	new|new[64]	_	_
8-9	1368-1379	Angiography	abstract[64]	new[64]	_	_
8-10	1380-1381	(	_	_	_	_
8-11	1382-1384	FA	abstract	giv	coref	10-23
8-12	1385-1386	)	_	_	_	_
8-13	1387-1395	provides	_	_	_	_
8-14	1396-1398	an	abstract[66]	new[66]	coref	10-22[85_66]
8-15	1399-1407	enhanced	abstract[66]	new[66]	_	_
8-16	1408-1421	visualization	abstract[66]	new[66]	_	_
8-17	1422-1424	of	abstract[66]	new[66]	_	_
8-18	1425-1428	the	abstract[66]|abstract[67]	new[66]|new[67]	_	_
8-19	1429-1436	retinal	abstract[66]|abstract[67]	new[66]|new[67]	_	_
8-20	1437-1445	vascular	abstract[66]|abstract[67]	new[66]|new[67]	_	_
8-21	1446-1455	structure	abstract[66]|abstract[67]	new[66]|new[67]	_	_
8-22	1456-1458	by	_	_	_	_
8-23	1459-1468	injecting	_	_	_	_
8-24	1469-1470	a	abstract[69]	new[69]	_	_
8-25	1471-1474	dye	substance|abstract[69]	new|new[69]	_	_
8-26	1475-1483	contrast	abstract[69]	new[69]	_	_
8-27	1484-1488	into	_	_	_	_
8-28	1489-1492	the	person[70]	giv[70]	coref	18-8[142_70]
8-29	1493-1500	patient	person[70]	giv[70]	_	_
8-30	1501-1502	.	_	_	_	_

#Text=With the Optical Coherence Tomography ( OCT ) , we can visualize and analyze volumetric scans of the inner retinal layers , non-invasively and in real time .
9-1	1503-1507	With	_	_	_	_
9-2	1508-1511	the	abstract[72]	new[72]	appos	9-7[0_72]
9-3	1512-1519	Optical	abstract[72]	new[72]	_	_
9-4	1520-1529	Coherence	abstract|abstract[72]	new|new[72]	coref	10-28
9-5	1530-1540	Tomography	abstract[72]	new[72]	_	_
9-6	1541-1542	(	_	_	_	_
9-7	1543-1546	OCT	abstract	giv	coref	10-3[78_0]
9-8	1547-1548	)	_	_	_	_
9-9	1549-1550	,	_	_	_	_
9-10	1551-1553	we	person	acc	_	_
9-11	1554-1557	can	_	_	_	_
9-12	1558-1567	visualize	abstract	new	coref|none	34-31[286_0]|9-12[0_286]
9-13	1568-1571	and	_	_	_	_
9-14	1572-1579	analyze	_	_	_	_
9-15	1580-1590	volumetric	abstract[75]	new[75]	_	_
9-16	1591-1596	scans	abstract[75]	new[75]	_	_
9-17	1597-1599	of	abstract[75]	new[75]	_	_
9-18	1600-1603	the	abstract[75]|object[76]	new[75]|new[76]	coref	12-11[100_76]
9-19	1604-1609	inner	abstract[75]|object[76]	new[75]|new[76]	_	_
9-20	1610-1617	retinal	abstract[75]|object[76]	new[75]|new[76]	_	_
9-21	1618-1624	layers	abstract[75]|object[76]	new[75]|new[76]	_	_
9-22	1625-1626	,	_	_	_	_
9-23	1627-1641	non-invasively	_	_	_	_
9-24	1642-1645	and	_	_	_	_
9-25	1646-1648	in	_	_	_	_
9-26	1649-1653	real	time[77]	new[77]	_	_
9-27	1654-1658	time	time[77]	new[77]	_	_
9-28	1659-1660	.	_	_	_	_

#Text=Based on the OCT and the FA characteristics , a new image modality appeared , combining both the OCT benefits and the FA visualization : the Optical Coherence Tomography by Angiography ( OCTA ) .
10-1	1661-1666	Based	_	_	_	_
10-2	1667-1669	on	_	_	_	_
10-3	1670-1673	the	abstract[78]	giv[78]	coref	10-19[0_78]
10-4	1674-1677	OCT	abstract[78]	giv[78]	_	_
10-5	1678-1681	and	_	_	_	_
10-6	1682-1685	the	abstract[79]	new[79]	coref	26-15[203_79]
10-7	1686-1688	FA	abstract[79]	new[79]	_	_
10-8	1689-1704	characteristics	abstract[79]	new[79]	_	_
10-9	1705-1706	,	_	_	_	_
10-10	1707-1708	a	abstract[81]	giv[81]	coref	11-4[93_81]
10-11	1709-1712	new	abstract[81]	giv[81]	_	_
10-12	1713-1718	image	abstract|abstract[81]	giv|giv[81]	coref	11-7
10-13	1719-1727	modality	abstract[81]	giv[81]	_	_
10-14	1728-1736	appeared	_	_	_	_
10-15	1737-1738	,	_	_	_	_
10-16	1739-1748	combining	_	_	_	_
10-17	1749-1753	both	abstract[83]	new[83]	_	_
10-18	1754-1757	the	abstract[83]	new[83]	_	_
10-19	1758-1761	OCT	abstract|abstract[83]	giv|new[83]	_	_
10-20	1762-1770	benefits	abstract[83]	new[83]	_	_
10-21	1771-1774	and	_	_	_	_
10-22	1775-1778	the	abstract[85]	giv[85]	appos	10-26[87_85]
10-23	1779-1781	FA	abstract|abstract[85]	giv|giv[85]	coref	10-31
10-24	1782-1795	visualization	abstract[85]	giv[85]	_	_
10-25	1796-1797	:	_	_	_	_
10-26	1798-1801	the	abstract[87]	giv[87]	appos	10-33[0_87]
10-27	1802-1809	Optical	abstract[87]	giv[87]	_	_
10-28	1810-1819	Coherence	abstract|abstract[87]	giv|giv[87]	_	_
10-29	1820-1830	Tomography	abstract[87]	giv[87]	_	_
10-30	1831-1833	by	abstract[87]	giv[87]	_	_
10-31	1834-1845	Angiography	abstract[87]|abstract	giv[87]|giv	_	_
10-32	1846-1847	(	_	_	_	_
10-33	1848-1852	OCTA	abstract	giv	coref	11-1
10-34	1853-1854	)	_	_	_	_
10-35	1855-1856	.	_	_	_	_

#Text=OCTA imaging constitutes the new ophthalmic image modality , and it is the first that allows an exhaustive and non-invasive vascular analysis of the retina .
11-1	1857-1861	OCTA	abstract|abstract[91]	giv|new[91]	coref	12-1
11-2	1862-1869	imaging	abstract[91]	new[91]	_	_
11-3	1870-1881	constitutes	_	_	_	_
11-4	1882-1885	the	abstract[93]	giv[93]	ana	11-11[0_93]
11-5	1886-1889	new	abstract[93]	giv[93]	_	_
11-6	1890-1900	ophthalmic	abstract[93]	giv[93]	_	_
11-7	1901-1906	image	abstract|abstract[93]	giv|giv[93]	coref	14-21
11-8	1907-1915	modality	abstract[93]	giv[93]	_	_
11-9	1916-1917	,	_	_	_	_
11-10	1918-1921	and	_	_	_	_
11-11	1922-1924	it	abstract	giv	coref	14-17[110_0]
11-12	1925-1927	is	_	_	_	_
11-13	1928-1931	the	_	_	_	_
11-14	1932-1937	first	_	_	_	_
11-15	1938-1942	that	_	_	_	_
11-16	1943-1949	allows	_	_	_	_
11-17	1950-1952	an	abstract[95]	giv[95]	_	_
11-18	1953-1963	exhaustive	abstract[95]	giv[95]	_	_
11-19	1964-1967	and	abstract[95]	giv[95]	_	_
11-20	1968-1980	non-invasive	abstract[95]	giv[95]	_	_
11-21	1981-1989	vascular	abstract[95]	giv[95]	_	_
11-22	1990-1998	analysis	abstract[95]	giv[95]	_	_
11-23	1999-2001	of	abstract[95]	giv[95]	_	_
11-24	2002-2005	the	abstract[95]|object[96]	giv[95]|new[96]	_	_
11-25	2006-2012	retina	abstract[95]|object[96]	giv[95]|new[96]	_	_
11-26	2013-2014	.	_	_	_	_

#Text=OCTA accurately represents the vascularity of the foveal region within the retinal layers .
12-1	2015-2019	OCTA	abstract	giv	coref	14-15
12-2	2020-2030	accurately	_	_	_	_
12-3	2031-2041	represents	abstract	new	coref|none	13-1[101_0]|12-3[0_101]
12-4	2042-2045	the	abstract[98]	new[98]	coref	16-15[0_98]
12-5	2046-2057	vascularity	abstract[98]	new[98]	_	_
12-6	2058-2060	of	abstract[98]	new[98]	_	_
12-7	2061-2064	the	abstract[98]|place[99]	new[98]|new[99]	coref	31-39[260_99]
12-8	2065-2071	foveal	abstract[98]|place[99]	new[98]|new[99]	_	_
12-9	2072-2078	region	abstract[98]|place[99]	new[98]|new[99]	_	_
12-10	2079-2085	within	abstract[98]|place[99]	new[98]|new[99]	_	_
12-11	2086-2089	the	abstract[98]|place[99]|object[100]	new[98]|new[99]|giv[100]	_	_
12-12	2090-2097	retinal	abstract[98]|place[99]|object[100]	new[98]|new[99]|giv[100]	_	_
12-13	2098-2104	layers	abstract[98]|place[99]|object[100]	new[98]|new[99]|giv[100]	_	_
12-14	2105-2106	.	_	_	_	_

#Text=This representation is extracted based on the blood movement in the eye microvasculature .
13-1	2107-2111	This	abstract[101]	new[101]	_	_
13-2	2112-2126	representation	abstract[101]	new[101]	_	_
13-3	2127-2129	is	_	_	_	_
13-4	2130-2139	extracted	_	_	_	_
13-5	2140-2145	based	_	_	_	_
13-6	2146-2148	on	_	_	_	_
13-7	2149-2152	the	event[103]	new[103]	_	_
13-8	2153-2158	blood	substance|event[103]	new|new[103]	coref	31-24
13-9	2159-2167	movement	event[103]	new[103]	_	_
13-10	2168-2170	in	event[103]	new[103]	_	_
13-11	2171-2174	the	event[103]|substance[105]	new[103]|new[105]	_	_
13-12	2175-2178	eye	event[103]|object|substance[105]	new[103]|giv|new[105]	_	_
13-13	2179-2195	microvasculature	event[103]|substance[105]	new[103]|new[105]	_	_
13-14	2196-2197	.	_	_	_	_

#Text=Given that numerous systematic and eye diseases are related with the microvascular circulation , OCTA constitutes a relevant new ophthalmic image modality that better aids the diagnosis and monitoring processes of these pathologies .
14-1	2198-2203	Given	_	_	_	_
14-2	2204-2208	that	_	_	_	_
14-3	2209-2217	numerous	abstract[106]	new[106]	coref	15-4[114_106]
14-4	2218-2228	systematic	abstract[106]	new[106]	_	_
14-5	2229-2232	and	abstract[106]	new[106]	_	_
14-6	2233-2236	eye	abstract[106]	new[106]	_	_
14-7	2237-2245	diseases	abstract[106]	new[106]	_	_
14-8	2246-2249	are	_	_	_	_
14-9	2250-2257	related	_	_	_	_
14-10	2258-2262	with	_	_	_	_
14-11	2263-2266	the	abstract[107]	new[107]	_	_
14-12	2267-2280	microvascular	abstract[107]	new[107]	_	_
14-13	2281-2292	circulation	abstract[107]	new[107]	_	_
14-14	2293-2294	,	_	_	_	_
14-15	2295-2299	OCTA	abstract	giv	coref	22-6
14-16	2300-2311	constitutes	_	_	_	_
14-17	2312-2313	a	abstract[110]	giv[110]	coref	22-5[164_110]
14-18	2314-2322	relevant	abstract[110]	giv[110]	_	_
14-19	2323-2326	new	abstract[110]	giv[110]	_	_
14-20	2327-2337	ophthalmic	abstract[110]	giv[110]	_	_
14-21	2338-2343	image	abstract|abstract[110]	giv|giv[110]	coref	22-7
14-22	2344-2352	modality	abstract[110]	giv[110]	_	_
14-23	2353-2357	that	abstract[110]	giv[110]	_	_
14-24	2358-2364	better	abstract[110]	giv[110]	_	_
14-25	2365-2369	aids	abstract[110]	giv[110]	_	_
14-26	2370-2373	the	abstract[110]|abstract[111]	giv[110]|new[111]	coref	27-15[214_111]
14-27	2374-2383	diagnosis	abstract[110]|abstract[111]	giv[110]|new[111]	_	_
14-28	2384-2387	and	abstract[110]	giv[110]	_	_
14-29	2388-2398	monitoring	abstract[110]	giv[110]	_	_
14-30	2399-2408	processes	abstract[110]|abstract[112]	giv[110]|giv[112]	_	_
14-31	2409-2411	of	abstract[110]|abstract[112]	giv[110]|giv[112]	_	_
14-32	2412-2417	these	abstract[110]|abstract[112]|abstract[113]	giv[110]|giv[112]|new[113]	coref	27-20[0_113]
14-33	2418-2429	pathologies	abstract[110]|abstract[112]|abstract[113]	giv[110]|giv[112]|new[113]	_	_
14-34	2430-2431	.	_	_	_	_

#Text=As reference , diseases such as diabetes can generate a Diabetic Retinopathy ( DR ) , which provokes microvascular problems in advanced stages of the disease , eventually producing total blindness in the worst case scenario .
15-1	2432-2434	As	_	_	_	_
15-2	2435-2444	reference	_	_	_	_
15-3	2445-2446	,	_	_	_	_
15-4	2447-2455	diseases	abstract[114]	giv[114]	coref	22-26[170_114]
15-5	2456-2460	such	abstract[114]	giv[114]	_	_
15-6	2461-2463	as	abstract[114]	giv[114]	_	_
15-7	2464-2472	diabetes	abstract[114]|abstract	giv[114]|new	_	_
15-8	2473-2476	can	_	_	_	_
15-9	2477-2485	generate	_	_	_	_
15-10	2486-2487	a	abstract[117]	new[117]	appos	15-14[0_117]
15-11	2488-2496	Diabetic	abstract|abstract[117]	new|new[117]	_	_
15-12	2497-2508	Retinopathy	abstract[117]	new[117]	_	_
15-13	2509-2510	(	_	_	_	_
15-14	2511-2513	DR	abstract	giv	coref	15-25[121_0]
15-15	2514-2515	)	_	_	_	_
15-16	2516-2517	,	_	_	_	_
15-17	2518-2523	which	_	_	_	_
15-18	2524-2532	provokes	_	_	_	_
15-19	2533-2546	microvascular	abstract[119]	new[119]	_	_
15-20	2547-2555	problems	abstract[119]	new[119]	_	_
15-21	2556-2558	in	_	_	_	_
15-22	2559-2567	advanced	abstract[120]	new[120]	_	_
15-23	2568-2574	stages	abstract[120]	new[120]	_	_
15-24	2575-2577	of	abstract[120]	new[120]	_	_
15-25	2578-2581	the	abstract[120]|abstract[121]	new[120]|giv[121]	coref	23-26[0_121]
15-26	2582-2589	disease	abstract[120]|abstract[121]	new[120]|giv[121]	_	_
15-27	2590-2591	,	_	_	_	_
15-28	2592-2602	eventually	_	_	_	_
15-29	2603-2612	producing	_	_	_	_
15-30	2613-2618	total	abstract[122]	new[122]	_	_
15-31	2619-2628	blindness	abstract[122]	new[122]	_	_
15-32	2629-2631	in	_	_	_	_
15-33	2632-2635	the	event[124]	new[124]	_	_
15-34	2636-2641	worst	abstract[123]|event[124]	new[123]|new[124]	_	_
15-35	2642-2646	case	abstract[123]|event[124]	new[123]|new[124]	_	_
15-36	2647-2655	scenario	event[124]	new[124]	_	_
15-37	2656-2657	.	_	_	_	_

#Text=Also , the Retinal Vein Occlusion ( RVO ) produces a problematic loss of vascularity and a progressive vision loss .
16-1	2658-2662	Also	_	_	_	_
16-2	2663-2664	,	_	_	_	_
16-3	2665-2668	the	abstract[127]	new[127]	appos	16-8[0_127]
16-4	2669-2676	Retinal	person|abstract[127]	new|new[127]	_	_
16-5	2677-2681	Vein	plant|abstract[127]	new|new[127]	_	_
16-6	2682-2691	Occlusion	abstract[127]	new[127]	_	_
16-7	2692-2693	(	_	_	_	_
16-8	2694-2697	RVO	abstract	giv	coref	23-28
16-9	2698-2699	)	_	_	_	_
16-10	2700-2708	produces	_	_	_	_
16-11	2709-2710	a	event[129]	new[129]	_	_
16-12	2711-2722	problematic	event[129]	new[129]	_	_
16-13	2723-2727	loss	event[129]	new[129]	_	_
16-14	2728-2730	of	event[129]	new[129]	_	_
16-15	2731-2742	vascularity	event[129]|abstract	new[129]|giv	ana	17-9
16-16	2743-2746	and	_	_	_	_
16-17	2747-2748	a	event[132]	new[132]	_	_
16-18	2749-2760	progressive	event[132]	new[132]	_	_
16-19	2761-2767	vision	abstract|event[132]	giv|new[132]	coref	33-21
16-20	2768-2772	loss	event[132]	new[132]	_	_
16-21	2773-2774	.	_	_	_	_

#Text=With these representative examples among many others , it is clear that the retinal vascular integrity is related with the Visual Acuity ( VA ) of the patients .
17-1	2775-2779	With	_	_	_	_
17-2	2780-2785	these	abstract[133]	new[133]	_	_
17-3	2786-2800	representative	abstract[133]	new[133]	_	_
17-4	2801-2809	examples	abstract[133]	new[133]	_	_
17-5	2810-2815	among	abstract[133]	new[133]	_	_
17-6	2816-2820	many	abstract[133]|abstract[134]	new[133]|new[134]	_	_
17-7	2821-2827	others	abstract[133]|abstract[134]	new[133]|new[134]	_	_
17-8	2828-2829	,	_	_	_	_
17-9	2830-2832	it	abstract	giv	coref	26-26[206_0]
17-10	2833-2835	is	_	_	_	_
17-11	2836-2841	clear	_	_	_	_
17-12	2842-2846	that	_	_	_	_
17-13	2847-2850	the	abstract[136]	new[136]	_	_
17-14	2851-2858	retinal	abstract[136]	new[136]	_	_
17-15	2859-2867	vascular	abstract[136]	new[136]	_	_
17-16	2868-2877	integrity	abstract[136]	new[136]	_	_
17-17	2878-2880	is	_	_	_	_
17-18	2881-2888	related	_	_	_	_
17-19	2889-2893	with	_	_	_	_
17-20	2894-2897	the	abstract[138]	new[138]	appos	17-24[0_138]
17-21	2898-2904	Visual	person|abstract[138]	new|new[138]	_	_
17-22	2905-2911	Acuity	abstract[138]	new[138]	_	_
17-23	2912-2913	(	_	_	_	_
17-24	2914-2916	VA	abstract	giv	coref	18-5[141_0]
17-25	2917-2918	)	_	_	_	_
17-26	2919-2921	of	_	_	_	_
17-27	2922-2925	the	person[140]	new[140]	ana	23-8[0_140]
17-28	2926-2934	patients	person[140]	new[140]	_	_
17-29	2935-2936	.	_	_	_	_

#Text=Commonly , to estimate the VA of a given patient , it is necessary to perform different rudimentary tests .
18-1	2937-2945	Commonly	_	_	_	_
18-2	2946-2947	,	_	_	_	_
18-3	2948-2950	to	_	_	_	_
18-4	2951-2959	estimate	_	_	_	_
18-5	2960-2963	the	abstract[141]	giv[141]	ana	18-12[0_141]
18-6	2964-2966	VA	abstract[141]	giv[141]	_	_
18-7	2967-2969	of	abstract[141]	giv[141]	_	_
18-8	2970-2971	a	abstract[141]|person[142]	giv[141]|giv[142]	coref	19-16[148_142]
18-9	2972-2977	given	abstract[141]|person[142]	giv[141]|giv[142]	_	_
18-10	2978-2985	patient	abstract[141]|person[142]	giv[141]|giv[142]	_	_
18-11	2986-2987	,	_	_	_	_
18-12	2988-2990	it	abstract	giv	coref	20-5
18-13	2991-2993	is	_	_	_	_
18-14	2994-3003	necessary	_	_	_	_
18-15	3004-3006	to	_	_	_	_
18-16	3007-3014	perform	_	_	_	_
18-17	3015-3024	different	abstract[144]	new[144]	coref	19-4[145_144]
18-18	3025-3036	rudimentary	abstract[144]	new[144]	_	_
18-19	3037-3042	tests	abstract[144]	new[144]	_	_
18-20	3043-3044	.	_	_	_	_

#Text=In particular , these tests are normally related with the analysis of the ability of the patient to observe characteristic objects of different sizes and at different distances .
19-1	3045-3047	In	_	_	_	_
19-2	3048-3058	particular	_	_	_	_
19-3	3059-3060	,	_	_	_	_
19-4	3061-3066	these	abstract[145]	giv[145]	_	_
19-5	3067-3072	tests	abstract[145]	giv[145]	_	_
19-6	3073-3076	are	_	_	_	_
19-7	3077-3085	normally	_	_	_	_
19-8	3086-3093	related	_	_	_	_
19-9	3094-3098	with	_	_	_	_
19-10	3099-3102	the	abstract[146]	new[146]	_	_
19-11	3103-3111	analysis	abstract[146]	new[146]	_	_
19-12	3112-3114	of	abstract[146]	new[146]	_	_
19-13	3115-3118	the	abstract[146]|abstract[147]	new[146]|new[147]	_	_
19-14	3119-3126	ability	abstract[146]|abstract[147]	new[146]|new[147]	_	_
19-15	3127-3129	of	abstract[146]|abstract[147]	new[146]|new[147]	_	_
19-16	3130-3133	the	abstract[146]|abstract[147]|person[148]	new[146]|new[147]|giv[148]	coref	24-17[188_148]
19-17	3134-3141	patient	abstract[146]|abstract[147]|person[148]	new[146]|new[147]|giv[148]	_	_
19-18	3142-3144	to	abstract[146]|abstract[147]|person[148]	new[146]|new[147]|giv[148]	_	_
19-19	3145-3152	observe	abstract[146]|abstract[147]|person[148]	new[146]|new[147]|giv[148]	_	_
19-20	3153-3167	characteristic	abstract[146]|abstract[147]|person[148]|object[149]	new[146]|new[147]|giv[148]|new[149]	_	_
19-21	3168-3175	objects	abstract[146]|abstract[147]|person[148]|object[149]	new[146]|new[147]|giv[148]|new[149]	_	_
19-22	3176-3178	of	abstract[146]|abstract[147]|person[148]|object[149]	new[146]|new[147]|giv[148]|new[149]	_	_
19-23	3179-3188	different	abstract[146]|abstract[147]|person[148]|object[149]|abstract[150]	new[146]|new[147]|giv[148]|new[149]|new[150]	_	_
19-24	3189-3194	sizes	abstract[146]|abstract[147]|person[148]|object[149]|abstract[150]	new[146]|new[147]|giv[148]|new[149]|new[150]	_	_
19-25	3195-3198	and	_	_	_	_
19-26	3199-3201	at	_	_	_	_
19-27	3202-3211	different	abstract[151]	new[151]	_	_
19-28	3212-3221	distances	abstract[151]	new[151]	_	_
19-29	3222-3223	.	_	_	_	_

#Text=Consequently , the final VA estimation is subjective whereas its process is tedious and slow .
20-1	3224-3236	Consequently	_	_	_	_
20-2	3237-3238	,	_	_	_	_
20-3	3239-3242	the	abstract[153]	new[153]	ana	20-10[0_153]
20-4	3243-3248	final	abstract[153]	new[153]	_	_
20-5	3249-3251	VA	abstract|abstract[153]	giv|new[153]	coref	23-11[174_0]
20-6	3252-3262	estimation	abstract[153]	new[153]	_	_
20-7	3263-3265	is	_	_	_	_
20-8	3266-3276	subjective	_	_	_	_
20-9	3277-3284	whereas	_	_	_	_
20-10	3285-3288	its	abstract|event[155]	giv|giv[155]	coref	21-12[159_155]
20-11	3289-3296	process	event[155]	giv[155]	_	_
20-12	3297-3299	is	_	_	_	_
20-13	3300-3307	tedious	_	_	_	_
20-14	3308-3311	and	_	_	_	_
20-15	3312-3316	slow	_	_	_	_
20-16	3317-3318	.	_	_	_	_

#Text=In that context , any technological contribution that avoids or facilitates this revision process is extremely desired in the ophthalmic field .
21-1	3319-3321	In	_	_	_	_
21-2	3322-3326	that	abstract[156]	new[156]	_	_
21-3	3327-3334	context	abstract[156]	new[156]	_	_
21-4	3335-3336	,	_	_	_	_
21-5	3337-3340	any	abstract[157]	new[157]	_	_
21-6	3341-3354	technological	abstract[157]	new[157]	_	_
21-7	3355-3367	contribution	abstract[157]	new[157]	_	_
21-8	3368-3372	that	abstract[157]	new[157]	_	_
21-9	3373-3379	avoids	abstract[157]	new[157]	_	_
21-10	3380-3382	or	abstract[157]	new[157]	_	_
21-11	3383-3394	facilitates	abstract[157]	new[157]	_	_
21-12	3395-3399	this	abstract[157]|event[159]	new[157]|giv[159]	_	_
21-13	3400-3408	revision	abstract[157]|event|event[159]	new[157]|new|giv[159]	_	_
21-14	3409-3416	process	abstract[157]|event[159]	new[157]|giv[159]	_	_
21-15	3417-3419	is	_	_	_	_
21-16	3420-3429	extremely	_	_	_	_
21-17	3430-3437	desired	_	_	_	_
21-18	3438-3440	in	_	_	_	_
21-19	3441-3444	the	abstract[160]	new[160]	coref	33-17[272_160]
21-20	3445-3455	ophthalmic	abstract[160]	new[160]	_	_
21-21	3456-3461	field	abstract[160]	new[160]	_	_
21-22	3462-3463	.	_	_	_	_

#Text=Given the potential of the OCTA image modality , over recent years , several clinical studies were published demonstrating its utility in the analysis of different vascular diseases .
22-1	3464-3469	Given	_	_	_	_
22-2	3470-3473	the	abstract[161]	new[161]	_	_
22-3	3474-3483	potential	abstract[161]	new[161]	_	_
22-4	3484-3486	of	abstract[161]	new[161]	_	_
22-5	3487-3490	the	abstract[161]|abstract[164]	new[161]|giv[164]	ana	22-20[0_164]
22-6	3491-3495	OCTA	abstract[161]|abstract|abstract[164]	new[161]|giv|giv[164]	coref	24-11
22-7	3496-3501	image	abstract[161]|abstract|abstract[164]	new[161]|giv|giv[164]	coref	27-23
22-8	3502-3510	modality	abstract[161]|abstract[164]	new[161]|giv[164]	_	_
22-9	3511-3512	,	_	_	_	_
22-10	3513-3517	over	_	_	_	_
22-11	3518-3524	recent	time[165]	giv[165]	_	_
22-12	3525-3530	years	time[165]	giv[165]	_	_
22-13	3531-3532	,	_	_	_	_
22-14	3533-3540	several	abstract[166]	new[166]	coref	24-1[183_166]
22-15	3541-3549	clinical	abstract[166]	new[166]	_	_
22-16	3550-3557	studies	abstract[166]	new[166]	_	_
22-17	3558-3562	were	_	_	_	_
22-18	3563-3572	published	_	_	_	_
22-19	3573-3586	demonstrating	_	_	_	_
22-20	3587-3590	its	abstract|abstract[168]	giv|new[168]	coref	27-22[218_0]
22-21	3591-3598	utility	abstract[168]	new[168]	_	_
22-22	3599-3601	in	_	_	_	_
22-23	3602-3605	the	abstract[169]	new[169]	coref	28-27[227_169]
22-24	3606-3614	analysis	abstract[169]	new[169]	_	_
22-25	3615-3617	of	abstract[169]	new[169]	_	_
22-26	3618-3627	different	abstract[169]|abstract[170]	new[169]|giv[170]	coref	23-26[182_170]
22-27	3628-3636	vascular	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
22-28	3637-3645	diseases	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
22-29	3646-3647	.	_	_	_	_

#Text=Hence , Balaratnasingam et al. demonstrated in their study that the VA is correlated with the Foveal Avascular Zone ( FAZ ) in patients with DR and RVO diseases .
23-1	3648-3653	Hence	_	_	_	_
23-2	3654-3655	,	_	_	_	_
23-3	3656-3671	Balaratnasingam	person	new	_	_
23-4	3672-3674	et	_	_	_	_
23-5	3675-3678	al.	_	_	_	_
23-6	3679-3691	demonstrated	_	_	_	_
23-7	3692-3694	in	_	_	_	_
23-8	3695-3700	their	person|abstract[173]	giv|new[173]	coref|coref	23-24[179_0]|30-23[243_173]
23-9	3701-3706	study	abstract[173]	new[173]	_	_
23-10	3707-3711	that	_	_	_	_
23-11	3712-3715	the	abstract[174]	giv[174]	coref	24-14[187_174]
23-12	3716-3718	VA	abstract[174]	giv[174]	_	_
23-13	3719-3721	is	_	_	_	_
23-14	3722-3732	correlated	_	_	_	_
23-15	3733-3737	with	_	_	_	_
23-16	3738-3741	the	abstract[177]	new[177]	appos	23-21[0_177]
23-17	3742-3748	Foveal	place|abstract[177]	new|new[177]	_	_
23-18	3749-3758	Avascular	abstract|abstract[177]	new|new[177]	_	_
23-19	3759-3763	Zone	abstract[177]	new[177]	_	_
23-20	3764-3765	(	_	_	_	_
23-21	3766-3769	FAZ	abstract	giv	coref	30-12[237_0]
23-22	3770-3771	)	_	_	_	_
23-23	3772-3774	in	_	_	_	_
23-24	3775-3783	patients	person[179]	giv[179]	_	_
23-25	3784-3788	with	person[179]	giv[179]	_	_
23-26	3789-3791	DR	person[179]|abstract|abstract[182]	giv[179]|giv|giv[182]	coref	26-11[200_0]
23-27	3792-3795	and	person[179]|abstract[182]	giv[179]|giv[182]	_	_
23-28	3796-3799	RVO	person[179]|abstract|abstract[182]	giv[179]|giv|giv[182]	_	_
23-29	3800-3808	diseases	person[179]|abstract[182]	giv[179]|giv[182]	_	_
23-30	3809-3810	.	_	_	_	_

#Text=Other clinical studies related different manual biomarkers extracted from the OCTA images with the VA of the patient .
24-1	3811-3816	Other	abstract[183]	giv[183]	_	_
24-2	3817-3825	clinical	abstract[183]	giv[183]	_	_
24-3	3826-3833	studies	abstract[183]	giv[183]	_	_
24-4	3834-3841	related	_	_	_	_
24-5	3842-3851	different	abstract[184]	new[184]	coref	28-14[221_184]
24-6	3852-3858	manual	abstract[184]	new[184]	_	_
24-7	3859-3869	biomarkers	abstract[184]	new[184]	_	_
24-8	3870-3879	extracted	abstract[184]	new[184]	_	_
24-9	3880-3884	from	abstract[184]	new[184]	_	_
24-10	3885-3888	the	abstract[184]|abstract[186]	new[184]|giv[186]	coref	28-17[223_186]
24-11	3889-3893	OCTA	abstract[184]|abstract|abstract[186]	new[184]|giv|giv[186]	coref	28-18
24-12	3894-3900	images	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
24-13	3901-3905	with	abstract[184]	new[184]	_	_
24-14	3906-3909	the	abstract[184]|abstract[187]	new[184]|giv[187]	_	_
24-15	3910-3912	VA	abstract[184]|abstract[187]	new[184]|giv[187]	_	_
24-16	3913-3915	of	abstract[184]|abstract[187]	new[184]|giv[187]	_	_
24-17	3916-3919	the	abstract[184]|abstract[187]|person[188]	new[184]|giv[187]|giv[188]	_	_
24-18	3920-3927	patient	abstract[184]|abstract[187]|person[188]	new[184]|giv[187]|giv[188]	_	_
24-19	3928-3929	.	_	_	_	_

#Text=Wei et al. demonstrated the adequate repeatability of the vascular density as representative biomarker in healthy subjects in both macular and optic disk regions .
25-1	3930-3933	Wei	person	new	coref	34-1
25-2	3934-3936	et	_	_	_	_
25-3	3937-3940	al.	_	_	_	_
25-4	3941-3953	demonstrated	_	_	_	_
25-5	3954-3957	the	abstract[190]	new[190]	_	_
25-6	3958-3966	adequate	abstract[190]	new[190]	_	_
25-7	3967-3980	repeatability	abstract[190]	new[190]	_	_
25-8	3981-3983	of	abstract[190]	new[190]	_	_
25-9	3984-3987	the	abstract[190]|abstract[191]	new[190]|new[191]	coref	29-17[233_191]
25-10	3988-3996	vascular	abstract[190]|abstract[191]	new[190]|new[191]	_	_
25-11	3997-4004	density	abstract[190]|abstract[191]	new[190]|new[191]	_	_
25-12	4005-4007	as	abstract[190]|abstract[191]	new[190]|new[191]	_	_
25-13	4008-4022	representative	abstract[190]|abstract[191]|abstract[192]	new[190]|new[191]|new[192]	_	_
25-14	4023-4032	biomarker	abstract[190]|abstract[191]|abstract[192]	new[190]|new[191]|new[192]	_	_
25-15	4033-4035	in	abstract[190]|abstract[191]|abstract[192]	new[190]|new[191]|new[192]	_	_
25-16	4036-4043	healthy	abstract[190]|abstract[191]|abstract[192]|animal[193]	new[190]|new[191]|new[192]|new[193]	_	_
25-17	4044-4052	subjects	abstract[190]|abstract[191]|abstract[192]|animal[193]	new[190]|new[191]|new[192]|new[193]	_	_
25-18	4053-4055	in	abstract[190]|abstract[191]|abstract[192]|animal[193]	new[190]|new[191]|new[192]|new[193]	_	_
25-19	4056-4060	both	abstract[190]|abstract[191]|abstract[192]|animal[193]|abstract[194]|place[196]	new[190]|new[191]|new[192]|new[193]|new[194]|new[196]	_	_
25-20	4061-4068	macular	abstract[190]|abstract[191]|abstract[192]|animal[193]|abstract[194]|place[196]	new[190]|new[191]|new[192]|new[193]|new[194]|new[196]	_	_
25-21	4069-4072	and	abstract[190]|abstract[191]|abstract[192]|animal[193]|place[196]	new[190]|new[191]|new[192]|new[193]|new[196]	_	_
25-22	4073-4078	optic	abstract[190]|abstract[191]|abstract[192]|animal[193]|place[196]	new[190]|new[191]|new[192]|new[193]|new[196]	_	_
25-23	4079-4083	disk	abstract[190]|abstract[191]|abstract[192]|animal[193]|object|place[196]	new[190]|new[191]|new[192]|new[193]|new|new[196]	_	_
25-24	4084-4091	regions	abstract[190]|abstract[191]|abstract[192]|animal[193]|place[196]	new[190]|new[191]|new[192]|new[193]|new[196]	_	_
25-25	4092-4093	.	_	_	_	_

#Text=Posteriorly , Vivien at al. , demonstrated the influence of the glaucoma disease over the vessel tree characteristics , obtaining as conclusions the absence of retinal vascularity in the pathological cases over a control group .
26-1	4094-4105	Posteriorly	_	_	_	_
26-2	4106-4107	,	_	_	_	_
26-3	4108-4114	Vivien	person[197]	new[197]	_	_
26-4	4115-4117	at	person[197]	new[197]	_	_
26-5	4118-4121	al.	person[197]	new[197]	_	_
26-6	4122-4123	,	_	_	_	_
26-7	4124-4136	demonstrated	_	_	_	_
26-8	4137-4140	the	abstract[198]	new[198]	_	_
26-9	4141-4150	influence	abstract[198]	new[198]	_	_
26-10	4151-4153	of	abstract[198]	new[198]	_	_
26-11	4154-4157	the	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
26-12	4158-4166	glaucoma	abstract[198]|abstract|abstract[200]	new[198]|new|giv[200]	_	_
26-13	4167-4174	disease	abstract[198]|abstract[200]	new[198]|giv[200]	_	_
26-14	4175-4179	over	abstract[198]	new[198]	_	_
26-15	4180-4183	the	abstract[198]|abstract[203]	new[198]|giv[203]	_	_
26-16	4184-4190	vessel	abstract[198]|object|plant[202]|abstract[203]	new[198]|new|new[202]|giv[203]	coref	31-16
26-17	4191-4195	tree	abstract[198]|plant[202]|abstract[203]	new[198]|new[202]|giv[203]	_	_
26-18	4196-4211	characteristics	abstract[198]|abstract[203]	new[198]|giv[203]	_	_
26-19	4212-4213	,	_	_	_	_
26-20	4214-4223	obtaining	_	_	_	_
26-21	4224-4226	as	_	_	_	_
26-22	4227-4238	conclusions	abstract	new	_	_
26-23	4239-4242	the	abstract[205]	new[205]	_	_
26-24	4243-4250	absence	abstract[205]	new[205]	_	_
26-25	4251-4253	of	abstract[205]	new[205]	_	_
26-26	4254-4261	retinal	abstract[205]|abstract[206]	new[205]|giv[206]	ana	27-2[0_206]
26-27	4262-4273	vascularity	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
26-28	4274-4276	in	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
26-29	4277-4280	the	abstract[205]|abstract[206]|abstract[207]	new[205]|giv[206]|new[207]	_	_
26-30	4281-4293	pathological	abstract[205]|abstract[206]|abstract[207]	new[205]|giv[206]|new[207]	_	_
26-31	4294-4299	cases	abstract[205]|abstract[206]|abstract[207]	new[205]|giv[206]|new[207]	_	_
26-32	4300-4304	over	abstract[205]|abstract[206]|abstract[207]	new[205]|giv[206]|new[207]	_	_
26-33	4305-4306	a	abstract[205]|abstract[206]|abstract[207]|animal[209]	new[205]|giv[206]|new[207]|new[209]	_	_
26-34	4307-4314	control	abstract[205]|abstract[206]|abstract[207]|abstract|animal[209]	new[205]|giv[206]|new[207]|new|new[209]	_	_
26-35	4315-4320	group	abstract[205]|abstract[206]|abstract[207]|animal[209]	new[205]|giv[206]|new[207]|new[209]	_	_
26-36	4321-4322	.	_	_	_	_

#Text=Given its novelty , there exists a limited number of computational proposals to aid the diagnosis and monitoring of pathologies with this image modality .
27-1	4323-4328	Given	_	_	_	_
27-2	4329-4332	its	abstract|abstract[211]	giv|new[211]	_	_
27-3	4333-4340	novelty	abstract[211]	new[211]	_	_
27-4	4341-4342	,	_	_	_	_
27-5	4343-4348	there	_	_	_	_
27-6	4349-4355	exists	_	_	_	_
27-7	4356-4357	a	abstract[212]	new[212]	_	_
27-8	4358-4365	limited	abstract[212]	new[212]	_	_
27-9	4366-4372	number	abstract[212]	new[212]	_	_
27-10	4373-4375	of	abstract[212]	new[212]	_	_
27-11	4376-4389	computational	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-12	4390-4399	proposals	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-13	4400-4402	to	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-14	4403-4406	aid	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-15	4407-4410	the	abstract[212]|abstract[213]|abstract[214]	new[212]|new[213]|giv[214]	_	_
27-16	4411-4420	diagnosis	abstract[212]|abstract[213]|abstract[214]	new[212]|new[213]|giv[214]	_	_
27-17	4421-4424	and	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-18	4425-4435	monitoring	abstract[212]|abstract[213]|event[215]	new[212]|new[213]|new[215]	_	_
27-19	4436-4438	of	abstract[212]|abstract[213]|event[215]	new[212]|new[213]|new[215]	_	_
27-20	4439-4450	pathologies	abstract[212]|abstract[213]|event[215]|abstract	new[212]|new[213]|new[215]|giv	_	_
27-21	4451-4455	with	abstract[212]|abstract[213]	new[212]|new[213]	_	_
27-22	4456-4460	this	abstract[212]|abstract[213]|abstract[218]	new[212]|new[213]|giv[218]	_	_
27-23	4461-4466	image	abstract[212]|abstract[213]|abstract|abstract[218]	new[212]|new[213]|giv|giv[218]	coref	28-23
27-24	4467-4475	modality	abstract[212]|abstract[213]|abstract[218]	new[212]|new[213]|giv[218]	_	_
27-25	4476-4477	.	_	_	_	_

#Text=In fact , the existing works are mainly based on the extraction of characteristic biomarkers in the OCTA images or improving the image quality to facilitate its posterior analysis .
28-1	4478-4480	In	_	_	_	_
28-2	4481-4485	fact	_	_	_	_
28-3	4486-4487	,	_	_	_	_
28-4	4488-4491	the	abstract[219]	new[219]	_	_
28-5	4492-4500	existing	abstract[219]	new[219]	_	_
28-6	4501-4506	works	abstract[219]	new[219]	_	_
28-7	4507-4510	are	_	_	_	_
28-8	4511-4517	mainly	_	_	_	_
28-9	4518-4523	based	_	_	_	_
28-10	4524-4526	on	_	_	_	_
28-11	4527-4530	the	event[220]	new[220]	_	_
28-12	4531-4541	extraction	event[220]	new[220]	_	_
28-13	4542-4544	of	event[220]	new[220]	_	_
28-14	4545-4559	characteristic	event[220]|abstract[221]	new[220]|giv[221]	_	_
28-15	4560-4570	biomarkers	event[220]|abstract[221]	new[220]|giv[221]	_	_
28-16	4571-4573	in	event[220]|abstract[221]	new[220]|giv[221]	_	_
28-17	4574-4577	the	event[220]|abstract[221]|abstract[223]	new[220]|giv[221]|giv[223]	coref	30-15[239_223]
28-18	4578-4582	OCTA	event[220]|abstract[221]|abstract|abstract[223]	new[220]|giv[221]|giv|giv[223]	coref	30-18
28-19	4583-4589	images	event[220]|abstract[221]|abstract[223]	new[220]|giv[221]|giv[223]	_	_
28-20	4590-4592	or	_	_	_	_
28-21	4593-4602	improving	_	_	_	_
28-22	4603-4606	the	abstract[225]	new[225]	coref	34-5[276_225]
28-23	4607-4612	image	abstract|abstract[225]	giv|new[225]	ana	28-27
28-24	4613-4620	quality	abstract[225]	new[225]	_	_
28-25	4621-4623	to	_	_	_	_
28-26	4624-4634	facilitate	_	_	_	_
28-27	4635-4638	its	abstract|abstract[227]	giv|giv[227]	coref	33-23[274_227]
28-28	4639-4648	posterior	abstract[227]	giv[227]	_	_
28-29	4649-4657	analysis	abstract[227]	giv[227]	_	_
28-30	4658-4659	.	_	_	_	_

#Text=As reference , Díaz et al. briefly introduced a method to automatically extract and measure generally the Vascular Density ( VD ) .
29-1	4660-4662	As	_	_	_	_
29-2	4663-4672	reference	abstract	new	_	_
29-3	4673-4674	,	_	_	_	_
29-4	4675-4679	Díaz	person	new	_	_
29-5	4680-4682	et	_	_	_	_
29-6	4683-4686	al.	person	new	_	_
29-7	4687-4694	briefly	_	_	_	_
29-8	4695-4705	introduced	_	_	_	_
29-9	4706-4707	a	abstract[231]	new[231]	coref	30-6[236_231]
29-10	4708-4714	method	abstract[231]	new[231]	_	_
29-11	4715-4717	to	abstract[231]	new[231]	_	_
29-12	4718-4731	automatically	abstract[231]	new[231]	_	_
29-13	4732-4739	extract	abstract[231]	new[231]	_	_
29-14	4740-4743	and	abstract[231]	new[231]	_	_
29-15	4744-4751	measure	abstract[231]	new[231]	_	_
29-16	4752-4761	generally	abstract[231]	new[231]	_	_
29-17	4762-4765	the	abstract[231]|abstract[233]	new[231]|giv[233]	appos	29-21[0_233]
29-18	4766-4774	Vascular	abstract[231]|abstract|abstract[233]	new[231]|new|giv[233]	_	_
29-19	4775-4782	Density	abstract[231]|abstract[233]	new[231]|giv[233]	_	_
29-20	4783-4784	(	_	_	_	_
29-21	4785-4787	VD	abstract	giv	_	_
29-22	4788-4789	)	_	_	_	_
29-23	4790-4791	.	_	_	_	_

#Text=Also , the authors proposed a method to extract and measure the FAZ in healthy and DR OCTA images and they performed a FAZ circularity study in healthy and pathological images .
30-1	4792-4796	Also	_	_	_	_
30-2	4797-4798	,	_	_	_	_
30-3	4799-4802	the	abstract[235]	new[235]	ana	30-21
30-4	4803-4810	authors	abstract[235]	new[235]	_	_
30-5	4811-4819	proposed	_	_	_	_
30-6	4820-4821	a	abstract[236]	giv[236]	coref	33-5[268_236]
30-7	4822-4828	method	abstract[236]	giv[236]	_	_
30-8	4829-4831	to	abstract[236]	giv[236]	_	_
30-9	4832-4839	extract	abstract[236]	giv[236]	_	_
30-10	4840-4843	and	abstract[236]	giv[236]	_	_
30-11	4844-4851	measure	abstract[236]	giv[236]	_	_
30-12	4852-4855	the	abstract[236]|abstract[237]	giv[236]|giv[237]	coref	30-24[0_237]
30-13	4856-4859	FAZ	abstract[236]|abstract[237]	giv[236]|giv[237]	_	_
30-14	4860-4862	in	abstract[236]|abstract[237]	giv[236]|giv[237]	_	_
30-15	4863-4870	healthy	abstract[236]|abstract[237]|abstract[239]	giv[236]|giv[237]|giv[239]	coref	30-28[244_239]
30-16	4871-4874	and	abstract[236]|abstract[237]|abstract[239]	giv[236]|giv[237]|giv[239]	_	_
30-17	4875-4877	DR	abstract[236]|abstract[237]|abstract[239]	giv[236]|giv[237]|giv[239]	_	_
30-18	4878-4882	OCTA	abstract[236]|abstract[237]|abstract|abstract[239]	giv[236]|giv[237]|giv|giv[239]	coref	31-10
30-19	4883-4889	images	abstract[236]|abstract[237]|abstract[239]	giv[236]|giv[237]|giv[239]	_	_
30-20	4890-4893	and	_	_	_	_
30-21	4894-4898	they	abstract	giv	ana	34-12
30-22	4899-4908	performed	_	_	_	_
30-23	4909-4910	a	abstract[243]	giv[243]	_	_
30-24	4911-4914	FAZ	abstract|abstract[243]	giv|giv[243]	coref	31-29
30-25	4915-4926	circularity	abstract|abstract[243]	new|giv[243]	_	_
30-26	4927-4932	study	abstract[243]	giv[243]	_	_
30-27	4933-4935	in	_	_	_	_
30-28	4936-4943	healthy	abstract[244]	giv[244]	coref	31-9[248_244]
30-29	4944-4947	and	abstract[244]	giv[244]	_	_
30-30	4948-4960	pathological	abstract[244]	giv[244]	_	_
30-31	4961-4967	images	abstract[244]	giv[244]	_	_
30-32	4968-4969	.	_	_	_	_

#Text=Alam et al. proposed different features extracted from the OCTA images , namely , the vessel tortuosity , the mean diameter of the blood vessels , the semi-automatic FAZ area , the FAZ irregularity and the density of the parafoveal avascular region using fractal dimensions .
31-1	4970-4974	Alam	person	new	_	_
31-2	4975-4977	et	_	_	_	_
31-3	4978-4981	al.	_	_	_	_
31-4	4982-4990	proposed	_	_	_	_
31-5	4991-5000	different	abstract[246]	new[246]	appos	31-13[250_246]
31-6	5001-5009	features	abstract[246]	new[246]	_	_
31-7	5010-5019	extracted	abstract[246]	new[246]	_	_
31-8	5020-5024	from	abstract[246]	new[246]	_	_
31-9	5025-5028	the	abstract[246]|abstract[248]	new[246]|giv[248]	coref	33-11[271_248]
31-10	5029-5033	OCTA	abstract[246]|abstract|abstract[248]	new[246]|giv|giv[248]	coref	33-13
31-11	5034-5040	images	abstract[246]|abstract[248]	new[246]|giv[248]	_	_
31-12	5041-5042	,	_	_	_	_
31-13	5043-5049	namely	abstract[250]|abstract[251]	giv[250]|giv[251]	appos|appos	31-13[251_250]|31-19[252_251]
31-14	5050-5051	,	abstract[250]|abstract[251]	giv[250]|giv[251]	_	_
31-15	5052-5055	the	abstract[250]|abstract[251]	giv[250]|giv[251]	_	_
31-16	5056-5062	vessel	object|abstract[250]|abstract[251]	giv|giv[250]|giv[251]	_	_
31-17	5063-5073	tortuosity	abstract[250]|abstract[251]	giv[250]|giv[251]	_	_
31-18	5074-5075	,	abstract[251]	giv[251]	_	_
31-19	5076-5079	the	abstract[251]|abstract[252]	giv[251]|giv[252]	appos	31-27[256_252]
31-20	5080-5084	mean	abstract[251]|abstract[252]	giv[251]|giv[252]	_	_
31-21	5085-5093	diameter	abstract[251]|abstract[252]	giv[251]|giv[252]	_	_
31-22	5094-5096	of	abstract[251]|abstract[252]	giv[251]|giv[252]	_	_
31-23	5097-5100	the	abstract[251]|abstract[252]|object[254]	giv[251]|giv[252]|new[254]	_	_
31-24	5101-5106	blood	abstract[251]|abstract[252]|substance|object[254]	giv[251]|giv[252]|giv|new[254]	_	_
31-25	5107-5114	vessels	abstract[251]|abstract[252]|object[254]	giv[251]|giv[252]|new[254]	_	_
31-26	5115-5116	,	abstract[251]	giv[251]	_	_
31-27	5117-5120	the	abstract[251]|abstract[256]	giv[251]|giv[256]	appos	31-32[258_256]
31-28	5121-5135	semi-automatic	abstract[251]|abstract[256]	giv[251]|giv[256]	_	_
31-29	5136-5139	FAZ	abstract[251]|abstract|abstract[256]	giv[251]|giv|giv[256]	coref	31-33
31-30	5140-5144	area	abstract[251]|abstract[256]	giv[251]|giv[256]	_	_
31-31	5145-5146	,	abstract[251]	giv[251]	_	_
31-32	5147-5150	the	abstract[251]|abstract[258]	giv[251]|giv[258]	appos	31-36[259_258]
31-33	5151-5154	FAZ	abstract[251]|abstract|abstract[258]	giv[251]|giv|giv[258]	_	_
31-34	5155-5167	irregularity	abstract[251]|abstract[258]	giv[251]|giv[258]	_	_
31-35	5168-5171	and	abstract[251]	giv[251]	_	_
31-36	5172-5175	the	abstract[251]|abstract[259]	giv[251]|giv[259]	_	_
31-37	5176-5183	density	abstract[251]|abstract[259]	giv[251]|giv[259]	_	_
31-38	5184-5186	of	abstract[251]|abstract[259]	giv[251]|giv[259]	_	_
31-39	5187-5190	the	abstract[251]|abstract[259]|place[260]	giv[251]|giv[259]|giv[260]	_	_
31-40	5191-5201	parafoveal	abstract[251]|abstract[259]|place[260]	giv[251]|giv[259]|giv[260]	_	_
31-41	5202-5211	avascular	abstract[251]|abstract[259]|place[260]	giv[251]|giv[259]|giv[260]	_	_
31-42	5212-5218	region	abstract[251]|abstract[259]|place[260]	giv[251]|giv[259]|giv[260]	_	_
31-43	5219-5224	using	abstract[251]|abstract[259]	giv[251]|giv[259]	_	_
31-44	5225-5232	fractal	abstract[251]|abstract[259]|abstract[261]	giv[251]|giv[259]|new[261]	_	_
31-45	5233-5243	dimensions	abstract[251]|abstract[259]|abstract[261]	giv[251]|giv[259]|new[261]	_	_
31-46	5244-5245	.	_	_	_	_

#Text=Guo et al. segmented and quantified avascular ischemic zones with map probabilities that were extracted by a deep convolutional neural network .
32-1	5246-5249	Guo	person	new	_	_
32-2	5250-5252	et	_	_	_	_
32-3	5253-5256	al.	_	_	_	_
32-4	5257-5266	segmented	_	_	_	_
32-5	5267-5270	and	_	_	_	_
32-6	5271-5281	quantified	_	_	_	_
32-7	5282-5291	avascular	place[263]	new[263]	_	_
32-8	5292-5300	ischemic	place[263]	new[263]	_	_
32-9	5301-5306	zones	place[263]	new[263]	_	_
32-10	5307-5311	with	place[263]	new[263]	_	_
32-11	5312-5315	map	place[263]|object|abstract[265]	new[263]|new|new[265]	_	_
32-12	5316-5329	probabilities	place[263]|abstract[265]	new[263]|new[265]	_	_
32-13	5330-5334	that	place[263]|abstract[265]	new[263]|new[265]	_	_
32-14	5335-5339	were	place[263]|abstract[265]	new[263]|new[265]	_	_
32-15	5340-5349	extracted	place[263]|abstract[265]	new[263]|new[265]	_	_
32-16	5350-5352	by	place[263]|abstract[265]	new[263]|new[265]	_	_
32-17	5353-5354	a	place[263]|abstract[265]|abstract[266]	new[263]|new[265]|new[266]	_	_
32-18	5355-5359	deep	place[263]|abstract[265]|abstract[266]	new[263]|new[265]|new[266]	_	_
32-19	5360-5373	convolutional	place[263]|abstract[265]|abstract[266]	new[263]|new[265]|new[266]	_	_
32-20	5374-5380	neural	place[263]|abstract[265]|abstract[266]	new[263]|new[265]|new[266]	_	_
32-21	5381-5388	network	place[263]|abstract[265]|abstract[266]	new[263]|new[265]|new[266]	_	_
32-22	5389-5390	.	_	_	_	_

#Text=Wang et al. proposed a method to produce mosaics using different overlapping OCTA images , increasing the wide field of vision for the posterior clinical analysis .
33-1	5391-5395	Wang	person	new	_	_
33-2	5396-5398	et	_	_	_	_
33-3	5399-5402	al.	_	_	_	_
33-4	5403-5411	proposed	_	_	_	_
33-5	5412-5413	a	abstract[268]	giv[268]	_	_
33-6	5414-5420	method	abstract[268]	giv[268]	_	_
33-7	5421-5423	to	abstract[268]	giv[268]	_	_
33-8	5424-5431	produce	abstract[268]	giv[268]	_	_
33-9	5432-5439	mosaics	abstract[268]|abstract	giv[268]|new	_	_
33-10	5440-5445	using	_	_	_	_
33-11	5446-5455	different	abstract[271]	giv[271]	coref	34-26[285_271]
33-12	5456-5467	overlapping	abstract[271]	giv[271]	_	_
33-13	5468-5472	OCTA	abstract|abstract[271]	giv|giv[271]	coref	34-9
33-14	5473-5479	images	abstract[271]	giv[271]	_	_
33-15	5480-5481	,	_	_	_	_
33-16	5482-5492	increasing	_	_	_	_
33-17	5493-5496	the	abstract[272]	giv[272]	_	_
33-18	5497-5501	wide	abstract[272]	giv[272]	_	_
33-19	5502-5507	field	abstract[272]	giv[272]	_	_
33-20	5508-5510	of	abstract[272]	giv[272]	_	_
33-21	5511-5517	vision	abstract[272]|abstract	giv[272]|giv	_	_
33-22	5518-5521	for	_	_	_	_
33-23	5522-5525	the	abstract[274]	giv[274]	_	_
33-24	5526-5535	posterior	abstract[274]	giv[274]	_	_
33-25	5536-5544	clinical	abstract[274]	giv[274]	_	_
33-26	5545-5553	analysis	abstract[274]	giv[274]	_	_
33-27	5554-5555	.	_	_	_	_

#Text=Wei et al. improved the quality of the OCTA scans in their work whereas Camino et al. identified existing shadow artifacts that typically appear in the OCTA images to improve the visualization and facilitate their inspection .
34-1	5556-5559	Wei	person	giv	_	_
34-2	5560-5562	et	_	_	_	_
34-3	5563-5566	al.	_	_	_	_
34-4	5567-5575	improved	_	_	_	_
34-5	5576-5579	the	abstract[276]	giv[276]	_	_
34-6	5580-5587	quality	abstract[276]	giv[276]	_	_
34-7	5588-5590	of	abstract[276]	giv[276]	_	_
34-8	5591-5594	the	abstract[276]|abstract[278]	giv[276]|new[278]	_	_
34-9	5595-5599	OCTA	abstract[276]|abstract|abstract[278]	giv[276]|giv|new[278]	coref	34-27
34-10	5600-5605	scans	abstract[276]|abstract[278]	giv[276]|new[278]	_	_
34-11	5606-5608	in	_	_	_	_
34-12	5609-5614	their	abstract|abstract[280]	giv|new[280]	ana	34-35
34-13	5615-5619	work	abstract[280]	new[280]	_	_
34-14	5620-5627	whereas	_	_	_	_
34-15	5628-5634	Camino	person	new	_	_
34-16	5635-5637	et	_	_	_	_
34-17	5638-5641	al.	_	_	_	_
34-18	5642-5652	identified	_	_	_	_
34-19	5653-5661	existing	object[283]	new[283]	_	_
34-20	5662-5668	shadow	abstract|object[283]	new|new[283]	_	_
34-21	5669-5678	artifacts	object[283]	new[283]	_	_
34-22	5679-5683	that	object[283]	new[283]	_	_
34-23	5684-5693	typically	object[283]	new[283]	_	_
34-24	5694-5700	appear	object[283]	new[283]	_	_
34-25	5701-5703	in	object[283]	new[283]	_	_
34-26	5704-5707	the	object[283]|abstract[285]	new[283]|giv[285]	_	_
34-27	5708-5712	OCTA	object[283]|abstract|abstract[285]	new[283]|giv|giv[285]	_	_
34-28	5713-5719	images	object[283]|abstract[285]	new[283]|giv[285]	_	_
34-29	5720-5722	to	_	_	_	_
34-30	5723-5730	improve	_	_	_	_
34-31	5731-5734	the	abstract[286]	new[286]	_	_
34-32	5735-5748	visualization	abstract[286]	new[286]	_	_
34-33	5749-5752	and	_	_	_	_
34-34	5753-5763	facilitate	_	_	_	_
34-35	5764-5769	their	abstract|event[288]	giv|new[288]	_	_
34-36	5770-5780	inspection	event[288]	new[288]	_	_
34-37	5781-5782	.	_	_	_	_
